Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Macy's Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.27 (market cap $29.60B), while Macy's Inc trades at $24.53 (market cap $6.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.6× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | M | |
|---|---|---|
Market Cap | $29.60B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $26.21 |
52-Week Low | $205.48 | $12.73 |
Enterprise Value | $27.56B | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Macy's (M) trades at $24.9, down 1.97% on the day, with a bullish technical signal and strong earnings beat history. The company shows improving fundamentals with net income margin recovery to 2.94% and positive cash flow trends. Recent institutional buying and analyst coverage reflects growing confidence in the turnaround strategy, though revenue declines remain a concern.
The stock presents value opportunity with attractive valuation multiples (P/E 10.13, P/S 0.3) and dividend yield. Upside potential exists to the $30 analyst target, but risks include ongoing revenue pressure and competitive retail environment. The successful execution of 'Bold New Chapter' strategy remains critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
